Table 1 Patient baseline characteristics. Results are presented as mean ± SD for normally distributed continuous variables, median (inter-quartile range) for non-normal variables and n (%) for categorical variables
All (N = 58) | Group A (N = 12) | Group B (N = 46) | p-value* | |
|---|---|---|---|---|
Age | 63 ± 6 | 65 ± 6 | 63 ± 7 | 0.37 |
BMI, kg/m2 | 27 ± 4 | 27 ± 5 | 27 ± 4 | 0.76 |
Hypertension | 20 (34 %) | 6 (50 %) | 14 (30 %) | 0.31 |
ACE or ARB | 14 (24 %) | 4 (33 %) | 10 (22 %) | 0.46 |
Beta-blocker | 7 (17 %) | 3 (25 %) | 4 (9 %) | 0.15 |
Calcium channel blocker | 4 (7 %) | 2 (17 %) | 2 (4 %) | 0.19 |
CAD | 1 (2 %) | 0 (0 %) | 1 (2 %) | 1.00 |
Statin use | 13 (22 %) | 3 (25 %) | 10 (22 %) | 1.00 |
Diabetes | 4 (7 %) | 1 (8 %) | 3 (7 %) | 1.00 |
Hypothyreosis | 8 (14 %) | 0 (0 %) | 8 (17 %) | 0.19 |
Current smoking | 8 (14 %) | 2 (17 %) | 6 (13 %) | 0.66 |
Hormonal therapy | 23 (40 %) | 4 (33 %) | 19 (41 %) | 1.00 |
AI | 22 (38 %) | 5 (42 %) | 17(37 %) | 0.75 |
Tamoxifen | 2 (3 %) | 0 (0 %) | 2 (4 %) | 1.00 |
Troponin T, ng/l | 4 (4–6) | 4(4–4.5) | 4 (4–7) | |
Cholesterol, mmol/l | 5.6 ± 1.1 | 5.5 ± 0.9 | 5.6 ± 1.1 | 0.90 |
BNP, ng/l | 58 (37–124) | 78 (33–123) | 58 (41–125) | 0.72 |